On September 9, 2025, Moleculin Biotech, Inc. announced the status of its Phase 2B/3 clinical trial, named the MIRACLE trial, investigating Annamycin in combination with cytarabine for treating acute myeloid leukemia. This global trial involves sites across the US, Europe, and the Middle East.